SE9401351D0 - A method for diagnosis - Google Patents

A method for diagnosis

Info

Publication number
SE9401351D0
SE9401351D0 SE9401351A SE9401351A SE9401351D0 SE 9401351 D0 SE9401351 D0 SE 9401351D0 SE 9401351 A SE9401351 A SE 9401351A SE 9401351 A SE9401351 A SE 9401351A SE 9401351 D0 SE9401351 D0 SE 9401351D0
Authority
SE
Sweden
Prior art keywords
pct
sec
human
date
individual
Prior art date
Application number
SE9401351A
Other languages
English (en)
Swedish (sv)
Inventor
Per Venge
Original Assignee
Venge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20393731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9401351(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Venge filed Critical Venge
Priority to SE9401351A priority Critical patent/SE9401351D0/xx
Publication of SE9401351D0 publication Critical patent/SE9401351D0/xx
Priority to DE69521608T priority patent/DE69521608T2/de
Priority to DK95917540T priority patent/DK0756708T3/da
Priority to AU23551/95A priority patent/AU2355195A/en
Priority to EP95917540A priority patent/EP0756708B1/de
Priority to PCT/SE1995/000439 priority patent/WO1995029404A1/en
Priority to ES95917540T priority patent/ES2160709T3/es
Priority to AT95917540T priority patent/ATE202849T1/de
Priority to JP52758295A priority patent/JP3544544B2/ja
Priority to US08/722,054 priority patent/US6136526A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SE9401351A 1994-04-21 1994-04-21 A method for diagnosis SE9401351D0 (sv)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SE9401351A SE9401351D0 (sv) 1994-04-21 1994-04-21 A method for diagnosis
US08/722,054 US6136526A (en) 1994-04-21 1995-04-21 Use of human neutrophil lipocalin (HNL) as a diagnostic marker and anti-HNL-antibody preparation
JP52758295A JP3544544B2 (ja) 1994-04-21 1995-04-21 診断マーカーとしてのヒト好中球リポカリン（ｈｎｌ）の使用および抗−ｈｎｌ−抗体調製物
AU23551/95A AU2355195A (en) 1994-04-21 1995-04-21 Use of human neutrophil lipocalin (hnl) as a diagnostic marker and anti-hnl-antibody preparation
DK95917540T DK0756708T3 (da) 1994-04-21 1995-04-21 Anvendelse af humant neutrophil-lipocalin (HNL) som en diagnostisk markør og anti-HNL-antistof-præparat
DE69521608T DE69521608T2 (de) 1994-04-21 1995-04-21 Verwendung von humanem neutrophil-lipocalin(hnl) als diagnostischer marker und anti-hnl-antikörperzubereitung
EP95917540A EP0756708B1 (de) 1994-04-21 1995-04-21 Verwendung von humanem neutrophil-lipocalin(hnl) als diagnostischer marker und anti-hnl-antikörperzubereitung
PCT/SE1995/000439 WO1995029404A1 (en) 1994-04-21 1995-04-21 Use of human neutrophil lipocalin (hnl) as a diagnostic marker and anti-hnl-antibody preparation
ES95917540T ES2160709T3 (es) 1994-04-21 1995-04-21 Uso de lipocalina de neutrofilos humanos (hnl) como un marcador de diagnostico y preparacion de anticuerpo anti-hnl.
AT95917540T ATE202849T1 (de) 1994-04-21 1995-04-21 Verwendung von humanem neutrophil-lipocalin(hnl) als diagnostischer marker und anti-hnl- antikörperzubereitung

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9401351A SE9401351D0 (sv) 1994-04-21 1994-04-21 A method for diagnosis

Publications (1)

Publication Number Publication Date
SE9401351D0 true SE9401351D0 (sv) 1994-04-21

Family

ID=20393731

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9401351A SE9401351D0 (sv) 1994-04-21 1994-04-21 A method for diagnosis

Country Status (10)

Country Link
US (1) US6136526A (de)
EP (1) EP0756708B1 (de)
JP (1) JP3544544B2 (de)
AT (1) ATE202849T1 (de)
AU (1) AU2355195A (de)
DE (1) DE69521608T2 (de)
DK (1) DK0756708T3 (de)
ES (1) ES2160709T3 (de)
SE (1) SE9401351D0 (de)
WO (1) WO1995029404A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1890000A (en) * 1998-12-28 2000-07-31 Kabushiki Kaisya Advance System for identifying microorganism
FI115165B (fi) 2001-06-04 2005-03-15 Aboatech Ab Oy Menetelmä infektion laadun määrittämiseksi
US20030119209A1 (en) * 2001-12-21 2003-06-26 Kaylor Rosann Marie Diagnostic methods and devices
US7056702B2 (en) * 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
EP2083270B1 (de) * 2003-03-27 2019-06-12 Children's Hospital Medical Center Verfahren und kit zum nachweis des frühstadiums einer nierentubuluszellenverletzung
ES2458636T3 (es) 2003-08-18 2014-05-06 Medimmune, Llc Humanización de anticuerpos
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
ES2818028T3 (es) 2004-12-20 2021-04-09 Antibodyshop As Determinación de lipocalina asociada a gelatinasa de neutrófilos (NGAL) como marcador diagnóstico para trastornos renales
AU2006227377B2 (en) 2005-03-18 2013-01-31 Medimmune, Llc Framework-shuffling of antibodies
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20070110757A1 (en) 2005-06-23 2007-05-17 Ziping Wei Antibody formulations having optimized aggregation and fragmentation profiles
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
PL2035835T3 (pl) 2006-05-30 2012-05-31 Antibodyshop As Sposoby szybkiej oceny ciężkości urazu
WO2008017306A1 (en) * 2006-08-07 2008-02-14 Antibodyshop A/S Diagnostic test to exclude significant renal injury
JP2010521694A (ja) * 2007-03-21 2010-06-24 バイオポルト・ダイアグノスティクス・アクティーゼルスカブ 腎傷害のための診断テスト
US8846036B2 (en) * 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090123946A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090124022A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
WO2009062520A1 (en) * 2007-11-15 2009-05-22 Bioporto Diagnostics A/S Diagnostic use of individual molecular forms of a biomarker
US8592170B2 (en) * 2008-03-12 2013-11-26 The Trustees Of Columbia University In The City Of New York High molecular weight Ngal as a biomarker for chronic kidney disease
US7977110B2 (en) * 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions
US20100105150A1 (en) * 2008-10-24 2010-04-29 Abbott Laboratories Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal
KR101939964B1 (ko) 2008-11-21 2019-01-18 퓨처 메디칼 다이아그노스틱스 코 엘티디 급성 신장 손상의 발견 또는 감시 방법, 장치 및 키트
US20100233739A1 (en) * 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to diagnose unilateral and bilateral urinary obstruction
CN103119444B (zh) 2010-04-21 2016-10-26 米密德诊断学有限公司 区分细菌与病毒感染的标记物和决定因素以及其使用方法
JP2013529907A (ja) 2010-05-24 2013-07-25 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Ｎｇａｌタンパク質変異体及びその使用
NL2007112C2 (en) 2011-07-14 2013-01-15 Brainlabs B V Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness.
EP2812700B1 (de) 2012-02-09 2018-04-18 Memed Diagnostics Ltd. Signaturen und determinanten zur diagnose von infektionen und verwendungsverfahren dafür
WO2014081980A2 (en) 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
JP6661607B2 (ja) 2014-08-14 2020-03-11 メメド ダイアグノスティクス リミテッド 多様体および超平面を用いる生物学的データのコンピュータ分析
WO2016059636A1 (en) 2014-10-14 2016-04-21 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
JP6788586B2 (ja) * 2014-11-19 2020-11-25 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． Ｈｎｌを用いる診断方法
CA2968650A1 (en) * 2014-12-11 2016-06-16 Memed Diagnostics Ltd. Marker combinations for diagnosing infections and methods of use thereof
CN108699583B (zh) 2016-03-03 2022-11-01 米密德诊断学有限公司 用于区分细菌和病毒感染的rna决定子
JP7112966B2 (ja) 2016-06-30 2022-08-04 シーメンス ヘルシニアーズ ネイザランド ビー．ブイ． 複数の細胞を含む体液試料内で分析物を検出するための装置、システム及び方法
EP3482200B1 (de) 2016-07-10 2022-05-04 Memed Diagnostics Ltd. Proteinsignaturen zur unterscheidung zwischen bakteriellen und viralen infektionen
CN109804245B (zh) 2016-07-10 2022-10-25 米密德诊断学有限公司 感染的早期诊断
EP3519834A4 (de) 2016-09-29 2020-06-17 MeMed Diagnostics Ltd. Verfahren zur risikobewertung und krankheitsklassifizierung
WO2018060998A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of prognosis and treatment
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US5200319A (en) * 1989-10-27 1993-04-06 The General Hospital Corporation Diagnosis of glomerulonephritis

Also Published As

Publication number Publication date
JPH09512630A (ja) 1997-12-16
EP0756708B1 (de) 2001-07-04
ES2160709T3 (es) 2001-11-16
AU2355195A (en) 1995-11-16
DE69521608T2 (de) 2002-05-08
ATE202849T1 (de) 2001-07-15
US6136526A (en) 2000-10-24
JP3544544B2 (ja) 2004-07-21
DE69521608D1 (de) 2001-08-09
EP0756708A1 (de) 1997-02-05
WO1995029404A1 (en) 1995-11-02
DK0756708T3 (da) 2001-10-29

Similar Documents

Publication Publication Date Title
SE9401351D0 (sv) A method for diagnosis
Patel et al. Estimation and comparison of salivary calcium, phosphorous, alkaline phosphatase and pH levels in periodontal health and disease: A cross-sectional biochemical study
Jepsen et al. Progressive peri‐implantitis. Incidence and prediction of peri‐implant attachment loss.
De Morais et al. Matrix metalloproteinase‐8 levels in periodontal disease patients: A systematic review
Dabra et al. Evaluating the levels of salivary alkaline and acid phosphatase activities as biochemical markers for periodontal disease: A case series
Isaza‐Guzmán et al. Salivary levels of NLRP3 inflammasome‐related proteins as potential biomarkers of periodontal clinical status
Zahavi et al. Enhanced in vivo platelet “release reaction” in old healthy individuals
Toeller et al. Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study
Kaldahl et al. Relationship of gingival bleeding, gingival suppuration, and supragingival plaque to attachment loss
Johnson et al. Detection of high‐risk groups and individuals for periodontal diseases: Evidence for the existence of high‐risk groups and individuals and approaches to their detection
Plagnat et al. Elastase, α2‐macroglobulin and alkaline phosphatase in crevicular fluid from implants with and without periimplantitis
ATE203329T1 (de) Verfahrens und testsätze zur diagnose periodentahlkrankheiten und zur vorhersage des risikos der progression davon
Babisch et al. Traffic noise and cardiovascular risk. The Caerphilly study, first phase. Outdoor noise levels and risk factors
Grbic et al. Risk indicators for future clinical attachment loss in adult periodontitis. Patient variables
Hanes et al. Characteristics of inflammation common to both diabetes and periodontitis: are predictive diagnosis and targeted preventive measures possible?
Oringer et al. C‐Telopeptide pyridinoline cross‐links (ICTP (and periodontal pathogens associated with endosseous oral implants
Albandar Some predictors of radiographic alveolar bone height reduction over 6 years
Ralls et al. Problems in identifying “bursts” of periodontal attachment loss
DE69510336D1 (de) Verfahren zur diagnose von praeklampsie
AU7260496A (en) A method and diagnostic test kit for use in aiding the diagnosis of fibromyyalgia and chronic fatigue syndrome (CFS)
Melamed et al. Type A behavior, tension, and ambulatory cardiovascular reactivity in workers exposed to noise stress.
Gupta et al. The influence of type 2 diabetes mellitus on salivary matrix metalloproteinase-8 levels and periodontal parameters: a study in an Indian population
Chen et al. Tooth loss patterns in older adults with special needs: a Minnesota cohort
Best et al. Reliability of attachment loss measurements in a longitudinal clinical trial
Rudra Mohan et al. The effect of nonsurgical periodontal therapy on pentraxin 3 levels in smokers and nonsmokers with chronic periodontitis